For early identification, accurate cognitive tests cutoff values for cognitive impairment are essential.<h4>Methods</h4>We conducted a study on 297 cognitively healthy elderly people from the BioFINDER study and created subgroups excluding people with signs of underlying neuropathology, i.e., abnormal cerebrospinal fluid [CSF] β-amyloid or phosphorylated tau, CSF neurofilament light (neurodegeneration), or cerebrovascular pathology. The gene discussed is MAPT; the disease is Cognitive impairment.